News on research and diagnostic development for pathogenic diseases.
Prenetics, which operates in 10 countries, will use the funding for R&D and plans to launch a rapid coronavirus nucleic acid test in Q4.
Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.
In 2018 Qiagen purchased a 19.9 percent stake in Ann Arbor, Michigan-based NeuMoDx along with the right to acquire the remaining shares.
The Manhattan-based lab will scale its capacity to process 20,000 tests per day by November and provide results dedicated to the city.
The company's revenues for the first half of the year were up over 900 percent on strong sales of its PCR-based SARS-CoV-2 test and related products.
